Table 1. Distribution of the Patient, Cancer, and Clinical Factors Stratified by Treatment Group for the 145 Patients in the Study Cohort.
| Clinical characteristic | Treatment groupa | |
|---|---|---|
| SOC (n = 67) | SOC plus docetaxel (n = 78) | |
| Race and ethnicity | ||
| Asian | 0 | 5 (6.4) |
| Black | 0 | 6 (7.7) |
| White | 57 (85.1) | 61 (78.2) |
| Otherb | 0 | 2 (2.6) |
| Unknown | 10 (14.9) | 4 (5.1) |
| Year of randomization | ||
| 2006-2011 | 44 (65.7) | 49 (62.8) |
| 2012-2015 | 23 (34.3) | 29 (37.2) |
| Age at randomization, median (IQR), y | 65 (61-69) | 62 (58-67) |
| ECOG performance status | ||
| 0 | 63 (94.0) | 76 (97.4) |
| 1 | 4 (6.0) | 2 (2.6) |
| Biopsy Gleason score | ||
| 8 | 27 (40.3) | 29 (37.2) |
| 9 | 37 (55.2) | 45 (57.7) |
| 10 | 3 (4.5) | 4 (5.1) |
| PSA level at randomization, median (IQR), ng/mL | 2.6 (1.5-3.2) | 2.5 (1.3-3.4) |
| Clinical tumor category | ||
| T1-TX | 13 (19.4) | 16 (20.5) |
| T2 | 29 (43.3) | 41 (52.6) |
| T3-T4 | 25 (37.3) | 21 (26.9) |
| Primary local therapy | ||
| External beam radiotherapy | 25 (37.3) | 26 (33.3) |
| Radical prostatectomy | 42 (62.7) | 52 (66.7) |
| Duration of ADT | ||
| Short-term (≤6 mo) | 49 (73.1) | 58 (74.4) |
| Long-term (2-3 y) | 18 (26.9) | 20 (25.6) |
| Follow-up, median (IQR), y | 7.3 (5.5-9.9) | 6.6 (5.3-9.7) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen.
SI conversion factor: To convert PSA to μg/L, multiply by 1.0.
a
Unless otherwise indicated, data are expressed as No. (%) of patients.
b
Includes American Indian or Alaska Native and Hispanic or Latino.